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ABSTRACT 
 
Background: The recognition of HIV/AIDS as a chronic life-long condition globally in recent 
years has demanded a different perception and an alignment to its association with other chronic 
diseases. Both HIV and other chronic non-communicable diseases are significant causes of 
morbidity and mortality. Their combined DALY contributions for Botswana would be significant 
if research and strategies in controlling these conditions are not put in place. Natural aging and 
specific HIV-related accelerated aging of patients who are on antiretroviral treatment means that 
age-related diseases will adversely affect this population.  
 
Princess Marina Hospital Infectious Diseases Care Clinic has been in operation since 2002. The 
clinic has initiated over 16 000 patients on anti-retroviral treatment (ART) since 2002. The 
current study estimated the prevalence of non-AIDS defining conditions (NADCs) in the 
attendees of the clinic in 2013. The majority of patients that attended the clinic had been on 
treatment for over three years with some patients more than ten years. These ART experienced 
patients were more likely to be susceptible to chronic non-communicable diseases, including 
non-AIDS defining conditions. The nomenclature used in classification of NADCs in the current 
study was appropriate for resource-limited settings; because the study setting offered HIV 
treatment under resources constraints.  
 
Aim: The current study characterised non-AIDS defining conditions, and determined their 
associations with virologic treatment failure in a cohort of patients that were enrolled at Princess 
Marina Hospital antiretroviral clinic in Gaborone, Botswana. 
 
Methods: A retrospective cross sectional study of records of patients who attended the Princess 
Marina Infectious Diseases Care Clinic in 2013. Stratified random sampling of a total of 228 
patients’ records was achieved from a total population of 5,781 records. Data was transcribed 
into a Microsoft Excel Spreadsheet and then exported to Epi-Info statistical software for analysis. 
 
Results: Eighty (35%) cases of NADCs were reported/diagnosed in the study sample; with 27% 
(n=62) of the patients having at least one condition, 6.7% (n=17) two conditions, and 0.4% (n=1) 
three conditions. The top prevalent conditions were hypertension (n= 40), hyperlipidaemia (n=7) 
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and lipodystrophy (n=7). The prevalence of NADCs on the various categories of patients 
compared with the total sample population was as follows: active patients (prevalence ratio= 
0.70), transferred out patients (prevalence ratio = 1.24), patients who died (prevalence 
ratio=2.04) and patients who were lost to follow-up (prevalence ratio =2.86). The prevalence of 
NADCs was significantly associated with increasing age (p<0.001); having social problems 
(p=0.028); having been on treatment for over three years (p=0.007); an outcome of death (p = 
0.03) and being lost to follow-up (p=0.007). The study showed that being controlled on second 
line or salvage regimen (p=0.014) and the presence of adherence problems in the past was 
associated with virologic failure (p=0.008). There was no association of presence of NADCs to 
virologic failure. 
 
Conclusions: There was significant morbidity of non-AIDS defining conditions in the Princess 
Marina Infectious Diseases Care Clinic shown by a prevalence of NADCs in the clinic of 35% in 
2013.The significant associations of the presence of NADCs and virologic failure with outcomes 
of death and loss to follow-up illustrate the adverse effects that NADCs are having, and calls for 
strategies to address multi-morbidities in HIV patients on antiretroviral treatment. 
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CHAPTER 1. INTRODUCTION 
 
1.1 Background 
According to the World Health Organisation (WHO) (2013), there were 35 million people 
globally living with HIV in 2013. Sub-Saharan Africa bears the brunt of the pandemic with 70% 
of the global disease. The Botswana AIDS Impact Survey 2013 found the national HIV 
prevalence in the population aged 18 months to 64 years as 19% (Botswana Central Statistics 
Office, 2013). The peak prevalence was in the age group 35 to 39 years with 43.7%.  
 
The Millennium Development Goals (MDGs) are a set of goals that were set by United Nations 
in September 2000 at the world summit of the United Nations (United Nations, 2000). There 
were eight (8) such goals in total - all targeted for the year 2015. These goals were packaged in a 
document adopted by the 149 member states that attended the United Nations General assembly 
in September 2000 called the “Millennium Declaration”. The document contained a statement of 
values, principles and objectives of the international agenda for the twenty-first century. MDG 6 
goal primarily addressed a group of diseases that included HIV, TB and Malaria and mandated 
countries to combat malaria, HIV/AIDS and other infectious diseases. These goals were 
reviewed periodically by countries and regions to identify bottlenecks in their implementation. In 
MDG 6 the United Nations General Assembly pledged to combat HIV/AIDS, malaria, 
tuberculosis and other infectious diseases. Many countries used MDG 6 as a yardstick to 
evaluate how they were performing in relation to combating HIV/AIDS, malaria, tuberculosis 
and other infectious diseases. 
 
The 2014 evaluation of the MDGs by UNAIDS have documented varying achievements in the 
different MDG goals in the world (United Nations, 2014). Southern Africa has seen some 
equivocal results with respect to MDG 6. Most of these results were negative. Gains made from 
running successful antiretroviral treatment (ART) programmes for HIV patients in countries such 
as Zimbabwe, Botswana and South Africa, have been met with losses in other areas. These losses 
included persisting new HIV infections especially in females of ages 15 to 24years (UNAIDS, 
2014). Exacerbations of new infections are mainly due to failures of behavioural change 
initiatives with regard to reducing alcohol use and unsafe sexual practices such as unprotected 
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sexual contact, multiple and concurrent sexual relationships and intergenerational sexual 
relationships (Delva and Abdool Karim, 2014; Harrison et al., 2015; United Nations, 2014). A 
high prevalence of HIV also leads to a large proportion of the general population with the 
chronic HIV disease and therefore carrier status of the infection. The high prevalence results in 
increased potential to spread the infection to the population that is not infected.  
 
With the target period of the MDGs drawing to an end, a world agenda on HIV/AIDS has been 
set by UNAIDS called ‘Agenda 2030 and post MDG’ (UNAIDS, 2014). This agenda focus is on 
elimination of the disease by 2030.  Whilst the failures of MDG6 particularly in the cluster of 
HIV/AIDS are evident, a more proactive scaled up approach to HIV/AIDS care has been 
designed in Agenda 2030. One of the programme goals is the 90-90-90 initiative where a 
commitment is made that by 2020: more than 90% of the HIV-infected population should know 
their HIV status, more than 90% of those eligible for treatment should be on regular treatment 
and that 90% of those on treatment should have virologic suppression. This commitment by 
UNAIDS and governments will need involvement of all stakeholders.  
 
For a successful Agenda 2030, UNAIDS calls for governments and civil societies of all 
countries, to identify implementable solutions to eliminate HIV/AIDS by 2030.  These should 
include policy, financing and dealing with issues such as stigma, discrimination, and making the 
most of civil society engagements (UNAIDS, 2015). Engagements would include making 
deliberate efforts to finance HIV treatment with antiretroviral drugs and implementing robust 
prevention strategies for all facets of society. 
 
In light of the above, recognition is made that in 2013 the World Health Assembly (WHA) made 
a commitment to lobby for a concerted effort to control non-communicable diseases (NCDs) 
(WHO, 2013). Section 27 of the pact calls for Ministries of Health from the member countries to: 
“Note with concern the possible linkages between non-communicable diseases and some 
communicable diseases, such as HIV/AIDS” (WHO, 2013, p. 14). The plight of NCDs and the 
recognition of HIV/AIDS as a communicable disease with a chronic status, enhance the need to 
make connections in relation to services for these diseases (Mahungu Rodger & Johnson, 2009). 
The current study recognises HIV/AIDS as an important condition that the world has to combat. 
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The study also recognises NCDs as important causes of morbidity that must be addressed. 
Hence, an appreciation of the prevalence of non-AIDS defining conditions (NADCs) in the urban 
antiretroviral clinic, in Botswana is a good starting point for the country and a yardstick for the 
future. 
 
The prevalence of NADCs in this centre presents an opportunity to find out the magnitude of 
these NCDs. The study achieved such baseline statistic, in which these NCDs are documented in 
a centre that was the first to commence antiretroviral treatment (ART)   in the country. It was 
also vital to determine the relationships, commonalities and treatment problems associated with 
NADCs and HIV/AIDS. Reconciling these relationships and problems is an attempt at realising 
the recommendation of the WHA of 2013, of appreciating linkages between HIV and NCDs.  
This is important for management of both the NCDs and HIV/AIDS.  
 
The main objectives of the study were; to determine the prevalence of NADCs in 2013 in 
Princess Marina IDCC, to describe clinical and socio-demographic characteristics of the cohort 
and describe problems of NADCs.  In addition a secondary objective was to determine if there 
was any association of presence of NADCs and HIV virologic treatment failure. The study 
documentation of the NADCs presents a starting point as the country make strategies to combat 
NCDs in HIV infected patients. 
 
1.2 HIV/AIDS and non-communicable diseases 
The plight of non-communicable diseases (NCDs) in HIV, including their prevalence, diagnosis 
and management, has been an area that has received a lot of attention in the literature. However, 
few studies were conducted in resource-poor settings (Hirschhorn et al., 2012). NCDs   increase 
in prevalence with advancing age. With control of HIV/AIDS by antiretroviral medicines, most 
HIV patients are aging and tend to succumb easily to non-communicable diseases. By and large 
most NCDs are not related to immune-suppression by HIV/AIDS. Some NCDs commonly occur 
in immune-competent HIV-infected patients and are referred to as non-AIDS defining conditions 
(NADCs) or non-AIDS defining events (NAEs). Classification of NADCs is not standard, and 
there are differing classifications for developed and developing countries, such as Botswana, 
which often provide ARV treatment under resource-poor settings. Hirchhorn et al. (2012) note 
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that in the studies in the developed countries classification tends to concentrate on cardiac, renal, 
hepatic and metabolic conditions, whilst  studies from resource poor countries report 
psychological, malignancies and non-AIDS-related respiratory conditions as additional examples 
of NADCs.  The current study utilises Hirchhorn et al. (2012)’s classification in recognition of 
Botswana as a provider of ARV treatment under resource-limited setting. 
 
Wester et al. (2011) and Hirchhorn et al. (2012) noted that there are variations in nomenclature 
of non-AIDS defining conditions. NADCs refer to conditions that are associated with HIV, but 
are non-AIDS-related. AIDS-related diseases are associated and emanate from immune-
suppression caused by AIDS. In this regard a cardiac condition like dilated cardiomyopathy,  can 
occur in the classification scheme of AIDS in the context of very low CD4 count, indicating 
severe disease and advanced disease by WHO classification (Botswana Ministry of Health, 2012; 
WHO, 2013). Such a condition is AIDS-related. When the condition occurs in the context of an 
immune competent HIV-infected patient, it is clearly not related to AIDS. This distinction is 
important because most of NADCs and NCDs have existed before HIV was discovered. In the 
context of another aetiology of chronic diseases, notably cancer, it is clear that cervical cancer, 
non Hodgkin Lymphoma and Kaposi sarcoma are agreeably AIDS-related; and therefore not 
NADCs (Ruiz et al., 2009). An important distinction is to highlight that NADCs have varying 
associations with HIV, as Ruiz et al. (2009) noted with some types of cancers. The authors 
observed varying degrees of associations of the different types of cancers and HIV infection. The 
current study described the prevalence of the NADCs with no emphasis on the degree of 
association to HIV infection. 
 
1.3 HIV Virologic treatment failure 
High virologic failure among patients on HIV treatment can be an indicator of poor performance 
of an ART programme (WHO, 2013). It must be mentioned that as a lone indicator it can be a 
subjective measure and may be applied assuming that all other indices such compliance and 
socio-economic status, that may have bearing on performance of an ART service, are equal. In 
addition, recent evidence  in relation to virologic treatment failure suggests  that in resources 
where viral load is done as part of an HIV treatment programme, other subjective measures such 
as  immunological (for example, CD4 count evaluations ) or clinical assessments may not add 
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value (Ford et al., 2013).  The authors note that when virologic measurements are in place they 
give better evaluation of how the clientele are doing relative to their care. Virologic status is a 
much more robust measure of failure or control of the patient. They argue that whilst CD4 count 
measurements by percentage may indicate good or poor immunologic status, the measure does 
not accurately indicate HIV treatment failure of the patient. Immunologic status may not reflect 
the failure or control status of patients because measurements such as CD4 counts have 
variations even amongst immune-competent patients (Williams et al., 2006). 
 
1.4 Treatment of HIV/AIDS in Botswana 
Botswana commenced treatment of eligible HIV patients with antiretroviral medicines in 2002 
(Farahani et al., 2014). By November 2012 more than 200 000 patients had been enrolled in 
various facilities spanning the country. These treatments have been made available by 
government at no cost to the patient. In addition, Farahani et al. (2014) observed that the HIV 
treatment programmes realized good outcomes in reducing mortality and morbidity associated 
with HIV. They measured mortality rate drops from 12.6, 1.16 and 0.15 per 100 person years, at 
three months, at 2 years and during the latter seven years of the review, respectively. It can be 
concluded that a sizeable proportion of patients under treatment live normal and productive lives, 
and that not many people are dying from the condition as was the case before commencement of 
antiretroviral treatment (ART).  
 
1.5 Description of the Study Setting 
The Princess Marina Hospital Infectious Disease Care Clinic, which started operation in 2002, 
was the first public outpatient clinic to provide antiretroviral treatment in Botswana. The 
Infectious Diseases Care Clinics (IDCCs) as these ART clinics are commonly known in 
Botswana, were started as a government initiative to directly treat infectious diseases mainly 
HIV and tuberculosis. The clinic in Princess Marina was the first clinic in the government 
programme for treatment for HIV infection with anti-retroviral drugs. Hence it has the oldest 
HIV patient cohort. It also serves as the main referral centre for HIV patients whose treatment is 
complicated by many factors, such as co-morbidities and HIV viral resistance. The clinic has 
initiated more than 16 000 patients on ART since its inception.  
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In Princess Marina Hospital, HIV/AIDS care is provided in one outpatient site, the IDCC, with 
other outpatients’ clinics, such as the diabetic clinic in the same hospital but at other sites. The 
ART clinics also provide some limited care to patients with non-communicable diseases. 
Majority of these patients rely on other outpatients’ clinics such as diabetic and medical 
outpatients’ clinics for care of NCDs. The facility is staffed by medical officers, nurses and HIV 
specialists including visiting specialists. There were eight (8) nurses, three (3) medical officers 
and five (5) HIV specialists that manned the facility at the time of the study.  Most of the patients 
had been transferred out to other ART clinics in relevant localities and by end of December 
2013, 5,758 patients were followed up at the clinic. These cohorts were patients with treatment 
problems or who were domiciled within the catchment area of the clinic. This translated to 
between 100 and 120 patients per day being followed up as outpatients. The Princess Marina 
Hospital IDCC also had a dedicated outpatient service for patients who had HIV treatment 
problems such as virologic failure, known as the HIV Failure Clinic. This service was run 
concurrently within the site to cater for patients with HIV treatment failure and had access to 
HIV specialists on regular basis. 
 
With a limited capacity both from human and material resources, the IDCC’s HIV Failure Clinic 
was managed by HIV specialists and medical officers in the absence of specialists. It is 
noteworthy that as this service is in what is a tertiary hospital in Botswana setting, the medical 
officers had access to telephonic consultations with the specialists. In addition there were 
Dermatology and Social Work clinics that consulted both ART and other patients.  
Since its inception, the Princess Marina Hospital IDCC has fared relatively well in the 
management of HIV. The successes of the clinic include: having managed to transfer out patients 
to other IDCCs that the centre also inducted in management of HIV (this includes other public 
sector and private sector clinics) and, maintaining a resource base for HIV care in the country 
whilst still fulfilling primary care IDCC function. However, some challenges remain. A high 
staff turnover, limitations in terms of material resources and HIV treatment-related issues are 
among the challenges in the centre. The other challenges include: constraints of follow-up of 
defaulters and a reduction in staff especially HIV specialists. These problems are partially 
associated with the receding of donor funding that has led to the HIV treatment program being 
almost entirely government-funded. 
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1.6 Problem Statement  
Non-AIDS defining conditions such as non-communicable diseases like diabetes and 
hypertension, and cancers are concerns that often have to be addressed in HIV treatment. The 
main reasons why these diseases increase in prevalence in the HIV-infected population is that 
patients on HIV treatment age and are susceptible to age related diseases such as NADCs. In 
addition this population is prone to other NCD-related risk factors such as smoking, alcohol use 
and obesity to name just a few. As the HIV pandemic matures there is need to identify and deal 
with more than one chronic disease, with the added burden of HIV or NCDs. Inevitably treating 
conditions that need, more often than not, life-long treatment is important. Their prevalence has 
not been documented sufficiently in Botswana both in the general population and in HIV-
infected people. Whilst operational problems are appreciated, some clinical and epidemiological 
studies about conditions in the patients have not been routinely documented. Co-morbid 
conditions have not been defined well in HIV patients in the IDCC. This is despite being high on 
the Botswana Ministry of Health Research Agenda (Botswana Ministry of Health, 2010; 
Botswana National AIDS Coordinating Agency, 2013). Furthermore, their association to 
virologic treatment failure amongst HIV patients has not been investigated in Princess Marina 
Hospital adult ARV clinic. Chronic diseases like diabetes, hypertension and cancer need to be 
treated by several drugs that may affect the efficacy of HIV drugs through interactions. In 
addition, poly-pharmacy problems, and the possibility of toxicity may be increased contributing 
to adverse drug reactions (ADRs), which may in the end have a bearing on HIV virologic 
treatment failure. The first line treatment failure rate in Princess Marina Infectious Diseases Care 
Clinic for 2013 was 3% and the second line HIV virologic treatment failure rate was 6% for the 
same year (IDCC, 2013). It is very important to keep this statistic as low as possible. Therefore, 
any factors that may alter this rate should be investigated and appropriate measures taken to 
address it. Any correlations that can be established with the NADCs will be important in the 
IDCC tackling of HIV treatment failure. 
 
Botswana ARV clinics, including the current site in Gaborone, have for over five (5) years been 
providing routine virologic load testing. It therefore became an added benefit to assess any 
association of NADCs prevalence with virologic treatment failure.  It must be mentioned that 
definitive virologic treatment failure to an HIV clinician is an emergency which must be 
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contained and whose rate must be kept low in a programme. It was also a secondary objective 
that was important to assess in the context of the Botswana HIV treatment programme as it offers 
virologic level testing. The presence of this test in the Botswana HIV programme is vital. 
Rutherford et al (2014) asserts that virologic treatment failure is more accurately confirmed by 
viral load testing compared to other assessments such as clinical or immunological assessments.  
Viral load testing as a confirmation of antiretroviral treatment failure has been utilised in PMH 
IDCC. It is likely that the patients that were documented as having been in failure were indeed in 
failure as far as Rutherford et al (2014) perspective holds. Association of virologic antiretroviral 
with NADCs or the lack thereof would inform the management of NADCs in patients who are 
failing HIV treatment.  
 
1.7 Outline of thesis 
In Chapter 2 the literature on non-AIDS defining conditions is visited with emphasis on studies 
done in sub-Saharan Africa. The review primarily focuses on HIV/AIDS, non-AIDS defining 
conditions and antiretroviral failure.  
 
Chapter 3 lays the methodology of the study. The thesis portrays a clear aim to determine 
prevalence of NADCs in the Princess Marina Hospital adult anti-retroviral clinic. The design, 
data collection and analysis methods are presented for the study. This details a cross-sectional 
analytic study of patients’ clinical outpatient records utilising a structured data capture tool. 
 
In Chapter 4 the study results are presented. An analysis of the results is made to present them 
with statistical parameters to allow interpretations, inferences and conclusions about them.  
 
Chapter 5 presents a brief discussion of the results making relevance to pertinent studies in the 
same topic.  
 
In Chapter 6, the conclusion and the study recommendations are drawn from the research 
findings. 
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CHAPTER 2. LITERATURE REVIEW 
 
2.1 Outline of literature review 
The literature was searched from the perspective of these two categories, HIV virologic 
treatment failure and non-AIDS defining conditions, as the main topics of interest This was done 
by searching for literature on using “co morbidities in HIV”, “HIV virologic treatment failure”, 
“non-AIDS defining conditions” and “HIV associated non-AIDS” in the University of Western 
Cape databases, notably EBSCOhost Web, Springerlink, Sage and Scopus. Other databases 
including online free access such as Google scholar were also accessed. The studies were chosen 
based on relevance to the present study. Combinations of the search terms were used to further 
sieve the literature, initially identifying studies whose designs were similar to this study, to assist 
in how best it could be carried out. Secondly an attempt to find high level evidence studies such 
as systematic reviews, meta-analyses or randomised controlled trials in this field was used to 
identify studies that have been elaborate and comprehensive in non-AIDS defining conditions or 
non-communicable diseases in HIV. 
 
The literature was also selected with a view to obtaining literature relevant to sub Saharan Africa 
of which Botswana is part. In addition, selective searches for HIV/ AIDS journals were also 
made to further redirect and adapt pertinent studies. There were no language restrictions in the 
search. Nevertheless studies that did not have an English translation version could not be used 
mainly due to a time constraint. In the review, grey literature was not used in this study. 
 
2.2 Definition of Non-AIDS Defining Conditions 
Non-AIDS defining conditions (NADCs) are conditions that occur in HIV-infected patients that 
are not related to the immune suppression caused by HIV. These typically include 
cardiovascular, renal, hepatic-related conditions and non-AIDS-related cancers (Wester et al., 
2011). Although, HIV/AIDS is an infectious disease it has recently been recognised as a chronic 
disease (Mahungu et al., 2009; Deeks Lewin and Havlir, 2013; Hayward, 2014). Furthermore, 
since HIV treatment prolongs the lives of HIV-infected patients, and prevalence of most 
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conditions like hypertension, type 2 diabetes increases with age; prevalence of these NADCs 
conditions will more likely increase with time amongst the HIV-infected who are on treatment 
and living long. 
 
Hirshhorn et al. (2012) classified NADCs into: non-AIDS defining malignancies, renal, 
cardiovascular, mental health and neuro-cognitive, osteoporosis and osteopenia and chronic 
respiratory disorders. It is vital to note that AIDS defining conditions are associated with low 
immunological and clinical status and were easily distinguishable as they occurred earlier on in 
the patient’s treatment. This is important for AIDS-related HIV-induced nephropathy, 
cardiomyopathies such as dilated cardiomyopathies that often occur at the lowest range of CD4 
count. Nevertheless pulmonary hypertension, essential hypertension and chronic renal failure 
that occur in the confines of an immune-competent patient are clearly NADCs (Barbaro, 2002; 
Cho and Kopp, 2004).  As Hirchhorn et al. (2012) and Lambert et al. (2015) observed, acute 
exacerbations of chronic obstructive pulmonary disease have an association with HIV infection. 
It is important to observe that some of the AIDS defining conditions may prevail even after 
immune-competence, meaning that they should not be captured as NADC. It must however be 
highlighted that in the study the patients selection i.e. a group of patients on HIV treatment for 
some time, were more likely to be affected by  NADC as opposed to AIDS-related diseases. This 
was because majority of patients were immune-competent and virologically suppressed on 
treatment. 
 
2.3 Non-AIDS Defining conditions associated with HIV 
The suggested associations of NADCs and HIV-infected status are multi-factorial and include 
lifestyle factors, immune response due to continued replication of the virus, and antiretroviral 
therapy. Demographics also have been suggested to play a role, with the aging population of 
patients on HAART and the increase of NCDs with increasing age (Wester et al., 2012). In 
addition, the inflammatory response posed by HIV-infected individuals has been suggested as 
the mechanism that gives a high risk of metabolic and vascular conditions (Hirshhorn et al., 
2012). Several studies have documented an increased prevalence of diabetes in patients on HIV 
treatment (Galli et al., 2012; Gapaeu et al., 2012).Hypertension and diabetes can occur as part of 
a syndrome called metabolic syndrome. This is a group of conditions which includes 
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hypertension, abnormal fat distribution around the waist and hip, abnormal lipid profile and 
abnormal sugar metabolism. Different organisations have definitive but related criteria. This 
abnormal fat distribution around the body is called lipodystrophy. It can imply either increased 
fat in some areas or reduced fat in other areas in the body or both (Briggs and Drabek, 2001; 
Mutimura et al., 2007; Vol Blanco et al., 2010). 
 
Some cardiovascular disease has been shown to be significantly higher in HIV-infected patients. 
In addition they call for a more vigilant approach to HIV treatment and caution with medications 
(Rolls et al., 2014). Myocardial infarction was observed to be increased in patients on HAART 
by the Data Collection on Adverse events of Anti-HIV Drugs (DAD) study (Justice et al., 2008; 
Worm et al., 2009). Hypertension has not been associated with a higher prevalence in HIV, with 
most population studies showing prevalence similar to the general population (Factor et al., 
2013; Munroe et al., 2012; Arruda Júnior et al., 2010). 
 
Wester et al. (2012) documented NADCs in a study utilizing a clinical trial in Botswana and 
compared the NADCs in the cohort with those observed in Nashville, Tennessee in the United 
States of America. Do et al. (2010) also documented some psychosocial co-morbidity, such as 
depression, alcohol abuse and social problems that were associated with poor adherence and 
treatment failure. 
 
Monroe et al. (2011) reported that most HIV clinicians are not comfortable treating medical 
conditions such as cardiovascular conditions but prefer to refer them to physicians. The study 
also revealed a correlation between poor diabetic control and hypertension to virologic treatment 
failure. This correlation may mean that on the converse, optimising diabetes and hypertension 
care may also improve HIV treatment. This study also identified a need to intensify adherence 
interventions to optimise care of co-morbidities. According to Viktil et al. (2007), poly-
pharmacy has been defined as the “concurrent use of multiple drugs” (p.187). Furthermore some 
researchers have discriminated between minor (two drugs) and major (more than four drugs) 
poly-pharmacy. Its problems have been associated with the effect of taking multiple 
medications/treatments. This often refers to the treatments cumulative effect on each other and 
on the conditions for which they are being taken (McCleod and Makay, 2008). Therefore the 
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medications have to be prescribed taking consideration of the others that are taken for the other 
diseases. Taking note of all these factors, an integrated model for the coordination of care of 
these patients with multiple morbidities may be warranted. Janssens et al. (2007) recommend 
one such a model of integrated clinics in Thailand, and detail its benefits which include 
convenience and cost benefits. Such benefits were also observed by Rolls et al. (2014) in London 
where the benefits of an HIV co-morbidity clinic were assessed. 
 
From having to manage more than one lifelong disease that needs several treatment modalities, it 
remains clear that, management of co-morbid NCDs such as hypertension and diabetes with HIV 
is a challenge that will need to be faced both from a clinical and policy perspective. Gineau and 
Hallen (2012) advocated for increased research into the association of NCDs with HIV infection. 
The authors also highlight how lessons learnt in HIV management may be of vital importance in 
NCD management. Management of HIV medicines compliance which is often done by pill 
counting of the actual tablets that the patient has remaining, may be one of the borrowed 
principles that can be used to check compliance to hypertension medicines for example. In 
addition if compliance to diabetes, hypertension or any other condition medication can be 
stressed like compliance to anti-retroviral treatment, these conditions may benefit from such 
emphasis. This would be important since non–compliance to such medication can lead to equally 
dangerous results such as stroke or myocardial infarction. Other areas such as healthy diet, 
avoidance of alcohol and tobacco use and the importance of exercise can be important benefits 
that are cross cutting and can benefit the HIV/ AIDS and the other conditions. Such integrated 
clinics could yield good results in areas of commonalities. 
 
Most of the literature on non-AIDS defining conditions is in resource rich settings and a majority 
of these studies have predominantly been on cardiovascular conditions (Blanco et al., 2010; 
Glenby, 2005). Some prevalence studies have been done on specific conditions such as 
hypertension and diabetes in HIV positive patients (Dusara et al., 2009; Hatsu et al., 2009). In 
Botswana a study by Wester et al. (2012) compared the incidence of NADCs in a Gaborone 
setting to an urban setting in Nashville Tennessee in America. The most common conditions 
were cardiovascular conditions. In addition the researchers found a comparatively similar 
incidence of NAEs in the two settings, but Botswana rates were higher on standardising for 
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population differences. That study acknowledged the problem of NADCs and recommended 
planning, monitoring, diagnosis and treatment of NADCs. In the review the literature relating to 
Botswana was limited in these conditions.  Save the study by Wester et al. (2012), two other 
studies involved estimation of prevalence of hypertension and diabetes respectively in cohorts 
that were going to be initiated on HAART (Dusara et al., 2009; Hatsu et al., 2009). These studies 
were conducted as part of a clinical trial establishing the safety and efficacy of antiretroviral 
treatments in Botswana. Hypertension was estimated at 18.5% by Dusara et al. (2009) in an HIV 
positive cohort in Botswana.  Diabetes mellitus was estimated at 4.6% in an HIV-infected cohort, 
compared to 7.2% in the general population by Hatsu et al. (2009). 
 
The Veterans Aging Cohort Study (VACS) and the DAD studies were the largest prospective 
multicentre studies that reported important associations of HIV including on prevalence of 
NADCs (Justice et al., 2008; Baker et al., 2009; Worm et al., 2009; Nurutdinova, 2012; 
Petoumenos et al., 2012). Such prospective studies meant that the patients were followed up in 
time and the conditions occurrences were observed and documented. In most of the studies the 
results showed significant prevalence of NCDs in patients who were on HIV treatment. Whilst 
the notion of NADCs or non-AIDS defining event (NADE) was evident in the literature, 
standardization of terminology has not been achieved. For example, the two main documents in 
the current review notably Wester et al. (2011) and Hirshhorn et al. (2012) classify them 
differently. Some of the literature was on mortalities associated with NADCs. It must be pointed 
out that mortality of non-AIDS defining conditions may surpass that of AIDS-related conditions 
as was shown in one prospective cohort study (Masia et al., 2013). The study also showed that 
HAART was protective against some NAEs notably psychiatric and renal diseases. Therefore 
NADCs are important to document and find any correlations or associations relative to 
HIV/AIDS. 
 
2.4 Virologic Treatment Failure among HIV patients 
According to WHO Guidelines on HIV treatment (2013), HIV virologic failure is defined as 
“plasma viral load above 1000 copies/ml based on two consecutive viral load measurements after 
three months, with adherence support”. This means that virologic failure is arrived at when two 
readings of viral load are persistently higher than 1000 copies per millilitre despite confirmed 
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adherence to medication. The definition of virologic failure as opposed to immunological or 
clinical failure needs reference viral load measures. This is opposed to CD4 count or clinical 
progression of HIV disease respectively in immunological and clinical failure. These are 
evidenced by symptomatic progression of the disease or by a deterioration of immunologic 
measures such as CD4 count. Virologic failure means that the HIV viral infection is not 
suppressed by treatment as it ought and often means the disease may progress. Rutherford et al. 
(2014) rationalise, after a systematic review of performance of WHO 2010 guidelines of 
immunologic and clinical guidelines that virologic measurements through viral load testing is a 
more reliable indicator of treatment failure. They concluded that virologic failure is best 
predicted by viral load testing as other modalities (such as immunologic assessments) do not 
predict it sufficiently.  
 
Some of associations of HIV treatment failure have been documented clearly in several studies; 
with majority of the studies being case control type studies (Datay et al., 2010; Merlin et al., 
2010; Sarmento-Castro, 2011; Krantz et al., 2011). Some prospective studies such as one by 
Montfort et al. (1998) all consistently pointed to adherence to antiretroviral treatment as the main 
determinant of HIV treatment failure. In addition the study reported that some specific HIV 
treatment regimen were more associated with failure. It is worth noting that some NADCs are 
associated with HIV treatment failure as detailed by Merlin et al. (2013), where   depression and 
other mood disorders, were shown to be associated with HIV treatment failure  
 
Studies that are of the same design as the current study include Sato and Okinawa (2013) who 
showed poly-pharmacy as a major deterrent of compliance.  One qualitative study reiterated that 
multiple morbidity in HIV cause distress and may sometimes cause problems of adherence 
(Monroe et al., 2014).  In one study Krantz et al. (2011) showed the presence of nevirapine in the 
initial regimen, treatment interruptions and low CD4 count at baseline as factors associated with 
virologic treatment failure in a case control study. Race and the presence of depressive 
symptoms were documented factors associated with failure by McFall et al. (2013). 
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As a collective for virologic treatment failure, Sarmento-Castro et al. (2011), summarise the 
factors associated with HIV virologic treatment failure and classify the factors as those relating 
to: the patient, the virus, and the treatment. Patient-related risk factors include sex, baseline CD4 
count, HIV staging at initiation whilst virus associated risk factors include resistant mutations. 
Treatment factors include efficacious medications, dosing, adverse drug reactions, and time to 
drug switch. 
 
It was reported, in most of the reviewed studies that different factors relating to failure had been 
observed. However, one consistently significant factor is non-adherence to medications 
(Sarmiento-Castro et al., 2011; Merlin et al., 2012). Pain, mood disorder and substance abuse 
were related with poor adherence in a study done by Merlin et al. (2012). Such psychological 
factors were observed by Do et al. (2010) in a study in Botswana. Therefore non-adherence 
seems to be the single most important factor that leads to virologic failure. This was evidenced 
by Ehlers and Tshisuyi (2015) in a recent cross sectional study in rural Botswana.   
 
2.5 Non-AIDS Defining Conditions and Anti-Retroviral Treatment Failure 
Co-morbidities have been established as a major reason necessitating drug switch. In a cross 
sectional study, performed in Tanzania Jima et al. (2007) documented that about 25% of drug 
switches that are being made are due to co-morbidities. Antiretroviral drugs have toxicities that 
can exacerbate chronic conditions.  
 
The systemic review of Hirschhorn et al. (2012) identifies some NCDs that have implications on 
anti-retroviral treatment. The authors note the tenfold risk of osteoporosis in HIV positive 
patients compared to age matched controls. Tenofovir is also associated with such osteopenia 
and osteoporosis. It is also worth noting that the systematic review document has revealed a 
slightly high prevalence rate of COPD in some studies. The association of mental illness, notably 
depression with adherence and anti-retroviral failure is corroborated by Hirshhorn et al. (2012) in 
agreement with studies elsewhere (Do et al., 2010).   
 
Non-AIDS defining cardiovascular conditions such as myocardial infarction have been 
associated with an atherogenic blood profile due to HIV infection (Ibouko Idoku and Ani, 2013). 
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The DAD study showed a significantly higher incidence of myocardial infarction in HIV patients 
compared to the general population (Worm et al., 2009). Some anti-retroviral treatments are 
contraindicated in dysrythmias so it is very important when treating these patients. HIV 
associated nephropathy is a common glomerulonephritis-type kidney disease that is often seen in 
HIV patients (Kagee, 2010). In addition some medications are nephrotoxic such as tenofovir. 
Hepatitis is often seen in the background of Hepatitis C or B infections as co-morbidities or can 
be seen on the background of treatment toxicity. Some non-AIDS malignancies such as Hodgkin 
disease and anal cancer have also been documented in HIV patients (Hirshhorn et al., 2012; 
Ruiz, 2009).  
 
Taking NADCs, HIV/AIDS and antiretroviral failure in context of the literature that was 
accessed, the following are worth noting. NADCs have been documented in several studies 
internationally and in Botswana. Their classification has not been standardised. In addition some 
NADCs such as cardiovascular conditions have been studied extensively in some countries, 
especially developed countries, whilst limited research has been done in resources limited 
settings. Treatment of NADCs is an important consideration in the management of HIV and vice 
versa. This was shown in the literature in form of: documented warrant of HIV treatment 
regimen change due to NADC, treatment toxicities exacerbating NADCs and drug-drug 
interactions. HIV treatment failure was shown to be mainly multi-factorial, with adherence to 
HIV treatment as the main problem across most of the studies. Some NADCs were shown to be 
associated more with antiretroviral failure. 
 
2.6 Summary of literature review 
 
As a broad agenda is set internationally for recognition of HIV/AIDS as a chronic disease, it 
became clear in this review that there is extensive literature on HIV and non-communicable 
diseases. Firstly, in Botswana prevalence studies have been on diseases such as diabetes and 
hypertension, each individually studied. Some studies were on HIV patients and others on the 
general population. Extensive international studies such as DAD study and VACS had given a 
redirection in the need for policy change. The studies have given impetus to World Health 
Organisation to recommend changes in guidelines of HIV treatment. In view to low income and 
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middle income countries settings, the literature showed several higher level evidence studies, 
including a systematic review and prospective cohort studies with various outcomes. There is a 
general observation in the studies that NCDs are a problem that must be addressed in the HIV-
infected population. 
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CHAPTER 3. METHODOLOGY 
 
3.1 Aims and Objectives 
The aims of this study were to determine the prevalence of non-AIDS defining conditions and 
their associations with virologic treatment failure in a cohort of HIV patients that were enrolled 
at the Princess Marina Infectious Diseases Care Clinic in 2013. 
 
The objectives of the study were to: 
1. determine the prevalence of NADCs; 
2. describe clinical and socio-demographic characteristics associated with the NADCs; 
3. describe treatment problems including drug interactions, adverse drug reactions and any 
other problem such as drug alterations due to NADCs treatment; and 
4. determine associations between prevalence of NADCs and virologic treatment failure. 
 
3.2 Study Design 
The study design was a retrospective, analytical cross-sectional design. This design was chosen 
because the aim of the study was to provide a baseline statistic. In addition the records were 
available in the clinic and could be easily accessed. Therefore there was a source of data that 
could be accessed easily. Other designs such as prospective studies would take a much longer 
time frame and require more resources. These were not feasible as this study had a time 
constraint.  The study involved accessing a sample of records of patients who had been seen in 
Princess Marina Hospital (Gaborone) in the year 2013 and establish a period prevalence of 
NADCs.  
 
3.3 Study Population and Sampling 
The arrangement of the filing of the Princess Marina Infectious Diseases Care Clinic was seen 
and it became clear that there is an organised filing system utilizing three personalised 
identifiers. However, it became clear that the electronic files and the actual personal files needed 
reconciliation. There was evidence that quality initiatives on the filing were being taken on an 
ongoing basis.  A records file audit that reconciled all files had been carried out in December 
2014.  This audit had reconciled both the electronic and the manual files.  According to the audit 
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that was carried in 2014, there were 5,578 patients who were regularly followed up in the clinic 
at the end of December 2013.  This was included 1,956 males and 3,922 females. In addition the 
site produced reports and maintained regular registers including those of all transfer outs, 
transfer-ins, deaths, lost to follow ups and active patients. There were 31 deaths, 129 transfers to 
other clinics and 43 patients declared lost to follow-up from the group that attended the IDCC in 
2013. Therefore the total population under study was 5,781 patients. During the pilot the data 
assistants were introduced to the facility staff. The clinic was toured and all areas that kept files 
were accessed. The study team was familiarized with the storage and retrieval of files from their 
locations. These included observations and practical retrieval of files from their locations. All 
registers and statistics were made available to the team. 
 
3.3.1 Case Definition 
For this study, non-AIDS defining conditions (NADCs) are defined as conditions that occur in 
HIV-infected patients that are not related to the immune suppression caused by HIV. Therefore 
all non-communicable diseases were eligible except if they are documented as AIDS defining. 
 
The following classification was used, which was based on the study by Hirschhorn et al. (2012): 
1. Non-AIDS-related Malignancies: 
All malignancies were recorded as cases except HIV/ AIDS associated below 
2. Cardiovascular diseases  
All chronic cardiovascular conditions that are not AIDS associated were regarded as 
cases, 
3. Chronic kidney diseases 
 All chronic kidney diseases that occurred in the confines of immune-competence were 
recorded 
4. Hepatic conditions were all recorded except conditions of an infective nature such as 
hepatitis related to viral hepatitis.  
5. Mental health and neuro-cognitive disorder 
 All psychological and mental health conditions  
6. Non communicable chronic respiratory diseases 
All chronic non communicable respiratory conditions were recorded 
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7. Osteoporosis, osteoarthritis and osteopenia 
8. Other chronic diseases- This case definition allowed for any chronic condition that had not 
been known to be associated with HIV, to be recorded. This was done such that cases that are 
clearly not-AIDS (immune suppression) associated conditions could be recorded. This was 
done knowing the current weakness of classifications. In the end it allowed an inclusion of 
cases that are definitely not AIDS-related but would not be exclusive to Hirchhorn et al. 
(2012) classification and thus enabled recording of such cases. 
Case Exclusions Criteria 
The following exclusions in the cases were made: 
1. Non Hodgkin lymphoma, cervical cancer and Kaposi sarcoma were excluded and treated 
as AIDS-related 
2. AIDS-related heart diseases such as stage 3 and 4 conditions e.g. dilated cardiomyopathy 
were excluded 
3. AIDS-related neuro-cognitive impairment such as known stage 3 and 4 conditions 
formerly known as ADC (Aids dementia complex) were excluded 
4. Chronic Infectious diseases such as viral hepatitis were excluded 
 
It is reiterated that infectious diseases were not included in this study as; that is, those that are 
related to HIV immune-suppression. Therefore, hepatitis due to infective causes was not 
included in this study. As stated earlier, hepatitis or herpetic conditions, to name a few, can and 
may be defined as chronic diseases. Hepatitis B related disease can be diagnosed in childhood or 
adulthood and maintain a chronic phase that is a diseased state without any sequelae, hence a 
chronic disease. These were excluded for the study because they are infectious diseases.  
 
3.3.2 Eligible study population 
 
The population under study was patients shown in medical records, who had attended Princess 
Marina Infectious Diseases Care Clinic in 2013 beginning on 01 January to 31 December 2013. 
Another inclusion criteria is that the patients whose records were included should have been aged 
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18 years and above in 2013. In the event that the record had not been in the age bracket of 18 and 
above, this record was excluded. Records of both male and females were included. 
 
Exclusion criteria  
The following exclusion criteria were applied on records: Data collected was going to be 
transcribed, so any record that showed destruction by wear and tear was judged ineligible, 
therefore excluded.  
 
3.3.3 Sampling 
The total study population of 5,781 was divided into four strata of 5,578 active patients, 129 
patients transferred out in 2013, 31 patients who had died in 2013 and 43 patients lost to follow-
up.  To maintain a power of 80% and 95% confidence intervals, the sample size required was 
calculated as 218 using Epi Info. This utilised a prevalence of NCDs of the general population by 
DALY of 18% (WHO, 2010). This was used because the prevalence of NADCs was not known 
in the population of interest it was decided that oversampling of the whole population should be 
done to take a population size of 300. This would compensate for an unknown prevalence and 
anticipated non-response. It came out clearly that the deaths, transfer outs and the lost to follow-
ups were a small proportion of the total population. It was then resolved that non-proportionate 
sampling should be employed in the smaller strata. This would give a more reliable 
representation of the outcome (Bruce, Pope and Stanistreet, 2008; Rothman and Greenland, 
1998), notably NADCs. At the end it was 15 files from the deaths, the lost to follow-up group 
each, and 60 files from the transferred group that were sampled, using a table of random 
numbers, generated against the non-name record identifiers.  
 
The 210 records in the active files were sampled using systematic random sampling through the 
patient’s attendance registers that are completed by doctors on daily basis. There were 678 such 
pages varying from 6 to 40 attendances. Using random numbers 678 numbers pages were 
sampled and three nth attendees were selected leading to 5th, 9th and the 31st attendees being 
randomly selected.  This sampling methodology was the only feasible one, since there was no 
uniform sampling frame. All the active patients’ files were kept with the more those 16000 files 
of patients that were ever started on treatment in the facility.  
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3.4 Data Collection 
The study used the annexed data collection tool. The annexed tool (Appendix 1) was the third 
and final version that was utilized after the pilot period. The files that were sampled were 
isolated and data extracted in a more presentable way. The data were expressed in the form of a 
spreadsheet using Microsoft excel, and were then cleaned using Microsoft Excel for 
typographical, duplicates and any ambiguous entries. 
 
The variables that were transcribed were divided four-fold: i) demographics including, location 
of living, gender, psychosocial issues and year of commencement of treatment ii) NADCs 
presence and treatment of NADCs iii) HIV treatment including treatment regimen, previous 
treatment switches and iv) virologic and immunological status including virologic control and 
CD4 count.  
 
3.5 Data Analysis 
Microsoft Excel was used to depict descriptive statistics, including frequencies and graphs. The   
main conditions which were measured were NADCs as detailed in the case definition. Virologic 
treatment failure was assessed as an a priori association along with other clinical and socio 
demographics. Furthermore, the data were imported into an Epi Info (Version 7.1.4.0) project 
file for analysing further associations including relationships between age and NADC presence. 
Chi-square tests were used to compare categorical variables. The significance level chosen was 
95% confidence level. This was because the same significance level was used in the sample 
selection.  
 
For multivariate analysis, logistic regression was used to determine the independent socio-
demographic and clinical characteristics for the prevalence of virologic treatment failure using 
parameters that had a p-value of <0.25 on univariate analysis.  Only presence of NADC was 
brought into the multivariate model with a p-value greater than 0.25 with the value of 0.26. The 
main rationale was that it was the main exposure of interest with relation to the study objective 
and the p-value was not far above cut off value.  
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3.6 Pilot Study 
The study was piloted at the site from 16 February 2015 to 18 February 2015. The data capture 
tool was piloted by having two doctors who were attending doctors at the clinic complete it 
based on patient records.  The tool was used for the records of patients who attended for the days 
of 16th to 18th February 2014.  The following factors came out as potential measurement errors.  
Demographics such as date of commencement of treatment, in particular the months were not 
consistent. It was decided that the year of commencement which became uniform should be 
used. Other variables notably employment status, alcohol use and smoking history were 
consistently not available and were taken off the tool.  There was a need to group the social 
problems together and have them as categories.  
 
On putting the question prompts to clarify the required variable the inter-user reliability scored at 
an average of 96% of all the variables scored. The intra-user consistency of the tool stood at 
100% for ten files used by two doctors. In total there were three versions of the tool that led to 
the final tool as seen in Appendix 1. 
 
The pilot period allowed the data assistants access to the records room and also to plan for how 
the records would be used and filed to allow continuity of care. The study rooms, liaison nurse 
for the study and other logistics for the study were all arranged during the pilot period. 
 
3.7 Validity and Reliability 
Validity is a measure of the accuracy of a test or instrument (Bruce, Pope and Stanistreet, 2009). 
Therefore the data capture tool ability to produce accurate results as detected from the records 
was important. This was fulfilled by piloting of the instrument and was achieved with an inter 
user agreement of 96%, i.e. taking cognizance of the variables that were scored by three groups 
of doctors. The kappa value for all the variables that were captured on the final version of the 
tool was 0.95, indicating a relatively robust tool. Reliability was assured by repeating 
transcription by the same doctors several hours after they had completed the questionnaires.  
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3.8 Generalisability 
The findings in this study were extrapolated to the Princess Marina Infectious Diseases Care 
Clinic for 2013 and not any other population. Whilst stratified random sampling was used using 
different sampling frame and oversampling, an argument is made that the population was a 
homogenous grouping with one common denominator of attendance of the IDCC in 2013. 
Nevertheless strata specific prevalence and analysis were done that were generalisable to the 
strata.  
 
3.9 Ethics Considerations  
The Hippocratic Oath that medical doctors subscribe to, mentions several tenets one of which 
states, “I will remember that I do not treat a fever chart, a cancerous growth, but a sick human 
being, whose illness may affect the person's family and economic stability. My responsibility 
includes these related problems, if I am to care adequately for the sick” (Tyson, 2014). Therefore 
it was important that as the patients’ charts were accessed and means established not to interfere 
with their clinical care. 
 
In agreement with above, Helsinki declaration of the World Medical Assembly articulates why 
the health, well-being and rights of patients, who are involved in medical research, must be 
protected. The physician's knowledge and research must also take account of these rights. The 
study was firstly granted approval by the University of the Western Cape Senate Research 
Committee. Thence it was granted permission by the Princess Marina Hospital Ethics Committee 
and the Health Research and Development Council (HRDC) in the Ministry of Health of 
Botswana. The HRDC advised that due to the time constraints, and as a study for academic 
reasons only, which does not undergo more rigorous ethical requirements, the application should 
enclose a request of waive of consent from patients whose files were sampled. 
 
The ethical clearance by the Princess Marina Hospital Ethics Committee was given on 4th 
February 2015. This was followed by the Ministry of Health of Botswana HRDC on 16th 
February 2015. As the national requirement all human health research a pilot could be carried 
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only when these two documents were available, therefore necessitating a shorter time period for 
pilot. 
 
It is recognised that this study did not involve human subjects directly although it involved 
human subjects’ data. The health research assistants were knowledgeable in issues of 
confidentiality as they were employed in a similar clinic elsewhere. They were sworn to 
confidentiality and a sample of the confidentiality pledge is attached in Appendix 4. Not 
anywhere were the names, confidential information used in accordance with the principles of 
respect, confidentiality and non-maleficence.  Only one non-name system identifier was used so 
that there could be a way to track a record in the case of clarifications in the file when requested. 
As a study that aims to inform the health system, it clearly has beneficence to the use of this 
hospital archive, to use to inform policy and practise. In the sampled files, three of the files had 
to be seen during the study period. Data capture was done a day prior to the patients’ 
consultation and the file returned. As such all the files were accessible when requested. All the 
files were filed back to their positions daily after transcription. 
 
 
  
 
 
 
 
 26 
 
CHAPTER 4. RESULTS 
 
4.1 Socio demographic and clinical characteristics of respondents 
There was a total eligible population of 5781 patients that attended the clinic in 2013, as shown 
in the sampling flow diagram in Figure 4.1. The categories of patients were: 5,578 patients who 
were active on site, 129 who were transferred out during the year, 31 patients who died and 43 
patients who were lost to follow-up. With an intended oversampling of 300, a total of 228 
records of those sampled were accessed with 150 from active patients, 14 from patients who had 
died 8 from patients who were lost to follow-up and 55 from patients who were transferred to 
other ARV sites in 2013. There was a total “non-response” of 24% overall which was seen as a 
result of unavailability of the records at their location. Only one record showed ineligibility as 
the reason for exclusion. 
 
 
 
 
 
   Categories                      Sampled                   Available                 Excluded 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Sampling flow diagram 
Eligible population 
    n=5781 
Active on site 
n=5578 
Died 
n=31 
Lost to follow-up 
n=43 
Transferred out 
n= 129 
 n=15 
n=210 
n=15 
n=55 
n=151 n=1 
n=8 
n=14 
n=60 
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The socio-demographic and clinical characteristics of the respondents are shown in Table 4.1 
below. The mean age and standard deviation of the patients were 45.3±19.5 years. A scatter plot 
of the distribution of ages is shown in Figure 4.2. It showed a relatively normal distribution of 
age as evidenced by the best line of fit plot. The age range was from 22 to 81 years and IQR 
was14 years. The male to female ratio was 1:1.52.  The location of living was documented in 204 
of the 228 patients. As can be seen of those whose location of living was known, about 64% of 
the population lived within 20km of Gaborone which was a classification given to those who 
lived in the city and villages around the city. The patients were commenced on treatment from 
2001 to 2013. The majority of patients had taken treatment for 5 to 10 years (56.3%). 
 
Pertaining to adherence and psychosocial factors, 29.4% of records showed evidence of the 
patient having had adherence problems in the past. These were in the forms of habitual 
defaulting, infrequent missing of doses and non-adherence related to social problems. As shown 
in Table 4.1, 22 of the records (9.5%) documented various social problems. Of these 22 patients 
different categories of problems were documented including transport (7), family problems (5), 
personal problems (11) and other social problems (6). Nine (9) records documented more than 
two categories of these problems. 
 
As seen in Table 4.1, the pre-treatment (baseline) CD4 count and the last CD4 count in the 
patients charts in 2013 were recorded. The baseline CD4 count ranged from 0 to 768 cells per 
cubic millilitre, with a median of 133 cells per cubic millilitre. The last CD4 count recorded in 
2013 ranged from 11 to 2006 cells per cubic millilitre and a median of 505 cells per cubic 
millilitre. This is CD4 count that was recorded after the patients had been on treatment for a 
while.  The CD4 counts categories are classified according to WHO immunological staging 
classification. It can be seen than the majority of CD4 counts in the baseline count were in the 
category of below 200 cells per cubic millilitre (79.7%). In contrast 52.5% (118) of the final 
CD4 counts recorded in 2013 were in the category of above 500 cells per cubic millilitre. The 
two groups of CD4 count were not normally distributed and the variances of the two counts were 
different. This was confirmed by an F test of variances (p< 0.001). As a result the two medians 
could not be statistically analysed for differences of the two groups. It is however noted that the 
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CD4 count in 2013 was greater than the baseline in more than 98% of respondents and it can be 
assumed that ART resulted in an increase in CD4 count. 
 
The treatment of the respondents with antiretroviral drugs was documented. As shown in table 
4.1 a majority of cases were treated on first line of treatment (85.5%) and on one of the following 
combinations: combivir/nevirapine (21.9%), combivir/evafirenz (25.9%), atripla (23.2%) and 
truvada/nevirapine (10.5%). The distribution of the regimen is shown in the table and as seen the 
most frequent combinations were combivir/evafirenz (25.9%) combivir/ nevirapine (23.2%), and 
atripla (21.9%). A total of 31 cases (13.6%) were on second line HIV treatment and only two 
patients (0.88%) were maintained on salvage regimen using four drugs. It is also noted that 125 
cases (54.8%) had never changed regimen in comparison with 103 (45.2%) who had treatment 
changes in the past. 
 
In all patients whose virologic status was known, 207 (90.8%) patients had their virologic status 
as controlled and 16 (7.0%) were classified as patients in virologic failure. One (1) patient had a 
viral blip. This is a case in which the viral load is elevated above 50 copies per millilitre on one 
occasion and then reverts to undetectable levels in subsequent tests. Four (4) patients had 
unrecorded virologic status because of an unrecorded viral load in scheduled visits in 2013. The 
HIV viral load blip and the cases with unrecorded virologic status were excluded in analysis 
involving virologic status. 
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Table 4.1 Socio-demographic and clinical characteristics of respondents 
 Frequency (n) Percentage (%) 
Gender                                  
Male   
Female                             
 
90 
137 
 
39.7 
60.3 
Age (years)              
         ≤ 30  
        31≤ 40                                  
        41≤50                                  
         51≤60                                
         61≤ 70                                 
          ≥71                                     
 
7 
70 
83 
55 
10 
3 
 
3.1 
30.7 
36.4 
24.1 
4.4 
1.3 
Duration of treatment        
Less than five years             
        Five to ten years                 
         Over ten years                    
 
48 
128 
51 
 
21.2 
56.3 
22.5 
Initial CD4 count (cells/mm3) 
0-199 
200-349 
350-499 
>500 
 
173 
31 
10 
3 
 
79.7 
14.3 
4.6 
1.4 
Final CD4 count (cells/mm3) 
0-199 
200-349 
350-499 
>500 
 
18 
43 
46 
118 
 
8.0 
19.1 
24.4 
52.5 
Adherence problems            
       Yes                                      
        No                                      
 
67 
161 
 
29.4 
70.6 
Social problems categories    
         None                                     
         Personal                                 
         Family                                  
         Transport                               
         Other                                    
         Multiple categories                 
 
204 
11 
5 
7 
6 
9 
 
89.5 
4.8 
2.1 
3.1 
2.6 
3.9 
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Distance from home                     
        Within 20km                         
         Between 20 and 40km            
         Between 40 and 100km          
         Within 500km                       
         Over 500km                        
 
130 
47 
8 
16 
3 
 
63.7                       
23.0         
3.9 
7.8 
1.5 
HIV Treatment categories       
         First line   
         Second line      
         Salvage treatment               
 
195 
31 
2 
 
85.5 
13.6  
0.88 
Treatment combinations 
Combivir/efavirenz         
Atripla                             
Combivir/ Nevirapine     
Truvada/ Nevirapine       
Truvada/ ALLU               
Combivir/ ALLU              
Abacavir/3TC/ALLU       
Abacavir/3TC/NVP          
Abacavir/3TC/EFV         
Atripla/ Abacavir              
ABC/TEN/ ALLU               
D4T/ATV/Vitrivir/3TC         
RAL/FTC/RTV/DRV              
           Tenofovir/3TC/Abacavir        
 
59 
53 
50 
24 
22 
5   
4 
2 
2 
2 
2 
1 
1
1
 
25.9 
23.2   
21.9     
10.5  
9.6 
2.2  
1.8 
0.9   
0.9 
0.9  
0.9   
0.4     
0.4  
0.4         
HIV treatment switches 
      No switches               
          Some switches              
 
125 
103 
 
54.8 
45.2 
Virologic status  
          Controlled                   
          Failure                          
 
207  
16 
 
92.8 
7.2 
Patient outcome                                 
           Active patients                 
          Transferred out                   
           Died                                   
           Lost to follow-up                 
 
150 
56 
14 
8 
 
65.8  
24.6 
6.1  
3.5                                
 
 
 
 
 
 31 
 
 
 
 
Figure 4.2: Age distribution of the respondents 
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4.2 Prevalence of Non-AIDS Defining Conditions 
There were 80 recorded cases of NADCs. All the cases are documented in Table 4.2. In total 62 
patients had evidence of one NADC, 16 patients had a second NADC and one patient had a third 
NADC. The prevalence of NADCs in the whole sample (of 228) calculates as 350 per 1000 
population. 
 
For active patients, thirty-eight (38) conditions were detected in 150 patients. Thirty (30) patients 
had one NADC only; seven (7) of them had a second NADC; and one (1) patient had a third 
NADC. The prevalence of NADCs in the active patients calculates as 254 per 1000, which 
translates to a prevalence ratio of 0.70.For respondents who died, ten (10) NADCs were detected. 
Seven (7) of these respondents had one NADC and three (3) respondents had a second NADC. 
This category consisted of fourteen (14) patients. The prevalence of NADCs in the respondents 
who died calculates as 714 per 1000population which translates to a prevalence ratio of 2.04. In 
patients who were transferred to other ARV sites, 21 patients had one NADC; with 3 of those 
(21) having a second NADC. The total number of respondents who were transferred to other 
sites was fifty-five (55). The prevalence of NADC was calculated as 436 per 1000population, 
which is equivalent to a prevalence ratio of 1.24. In patients who were lost to follow-up, 6 
patients had one NADC with 2 having second NADC. The number of respondents who were lost 
to follow-up was eight (8). The prevalence of NADCs translated to 1000 cases per 1000 
population and a resultant prevalence ratio of 2.86. 
 
Hypertension was the most frequent NADCs with 40 cases reported. Using Hirshhorn et al.’s 
(2012) classification it is noted that the conditions can be divided into the following: Non-HIV-
related cancers (3), Cardiovascular diseases (48), and Psychological/Mental problems (3), 
Metabolic (17), Chronic Kidney Disease (2) and lastly Other Conditions (7). 
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Table 4.2: Prevalence of the Non-AIDS defining conditions 
 
 
 
 
 
 
 
Category of disease  Frequency 
Cardiovascular  Hypertension 40 
 Erectile Dysfunction 3 
 Cerebro-vascular Accident 2  
 Congestive Cardiac Failure 1 
 Left Ventricular Hypertrophy  1  
 Varicose Veins/ venous Ulcers 1 
Metabolic Hyperlipidaemia 7 
 Lipodystrophy  7 
 Diabetes Mellitus Type II 3 
 Gynaecomastia 1 
Psychological/mental health Alcohol Abuse 2  
 Schizophrenia 1  
Chronic kidney disease Chronic Renal Failure 2 
Non-HIV-related 
malignancy 
Advanced colon cancer 1 
Advanced Cancer Of The Bladder 1 
 Advanced Breast Cancer 1 
Other Chronic Allergic Rhinitis 1  
 Benign Prostatic Hyperplasia  1 
 Menorrhagia 1 
 Osteoarthritis 1 
 Hypothyroidism 1 
 Coagulopathy 1 
Total number of NADCS 
 
80   
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4.3 Treatment of Non-AIDS Defining Conditions 
Treatment of the NADCs was documented in the records. Table 4.3 shows the level of control of 
the prevalent conditions. The control of the condition was captured based on the written 
documentation of control in the chart or evidence of clinical indicators such as blood pressure or 
other profile that are documented consistently within normal values. For all the conditions, the 
level of control of all the NADCs was as follows: 60% (48) of conditions were controlled, 21.2% 
(17) were uncontrolled, 7.5% (6) were progressive and for 11.3% (9), the control was unknown.   
 
The level of control of the three most common conditions hypertension, lipodystrophy and 
hyperlipidaemia is also shown. Thirty (30) of the cases of hypertension (75%) were controlled, 
compared to 8(20%) which were uncontrolled and 2 (5%) whose control was not known. The 
cases of hypertension were managed on lifestyle modification such as diet, exercise and alcohol 
avoidance and on antihypertensive medications. The combinations of these antihypertensive 
drugs included single drug therapies and multiple drug treatments. All treatment of lipodystrophy 
involved switching of the anti-retroviral drugs usually involving removal of stavudine or 
zidovudine, which are the drugs that are mainly associated with lipodystrophy. Two (2) cases of 
lipodystrophy were uncontrolled compared with five (5) cases that were controlled. 
Hyperlipidaemia was treated using lifestyle modifications mainly entailing diet and exercise and 
only 2 cases were treated with atorvastatin, a lipid lowering drug. All the cases of 
hyperlipidaemia were controlled on treatment.  
 
Treatment of other conditions such as malignancies, diabetes and some cases of hypertension 
were managed at other outpatient settings, and had no management documented in the charts. 
These contributed to the proportion whose control could not be determined from the records. It is 
observed that some of the NADCs were progressive, in particular the malignancies. In total 12 
cases (15%) were referred for management at other outpatients departments namely Urology (2), 
Oncology (3), Social Work (3), Ear Nose and Throat (1), Dermatology (1)  Gynaecology (1) and 
Cardiology (1). 
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Table 4.3 Control of the prevalent non-AIDS defining conditions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Condition (frequency) Percentage of condition controlled (%) 
Hypertension (40) 75 
Erectile Dysfunction (3) 33 
Cerebro-vascular Accident (2) 0 
Congestive Cardiac Failure(1) 100 
Left Ventricular Hypertrophy (1)  0 
Varicose Veins/ venous Ulcers (1) 0 
Hyperlipidaemia (7) 100 
Lipodystrophy (7) 71 
Diabetes Mellitus Type II (3) 0 
Gynaecomastia (1) 100 
Alcohol Abuse (2) 0 
Schizophrenia (1) 100 
Chronic Renal Failure (2) 0 
Advanced Colon Cancer (1) 0 
Advanced Bladder Cancer (1) 0 
Advanced Breast Cancer (1) 0 
Chronic Allergic Rhinitis (1) 0 
Benign Prostatic Hyperplasia (1) 0 
Menorrhagia (1) 0 
Osteoarthritis (1) 100 
Hypothyroidism (1) 100 
Coagulopathy (1) 100 
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4.4 Associations of Non-AIDS Defining Conditions 
 
Table 4.4 is a summary of associations that were tested against the prevalence of NADCs. Age 
was assessed by dividing age into two categories, below 50 years and 50 years and above. This 
was done because NCDs prevalence increases with age. Fifty was chosen as a cut point on 
considering that most NCDs start increasing progressively above 50 years of age. The study also 
took cognisance of the range of ages that were observed in the study of 22-81 years. 
 
There were statistically significant associations between age and the presence of one NADC 
(p<0.001) and two NADCs (p= 0.03). Those respondents who were 50 years and older had three 
times the odds of having at least one NADC compared to those younger than 50 years (OR = 
2.96[1.61-5.42). Presence of social problems was also significantly associated with presence of 
NADCs (p = 0.028). All the social problems categories were grouped together into presence or 
absence of social problems, without analysing separate ones individually. This was mainly due to 
the small numbers involved with individual social problems. Those respondents who had social 
problems had almost two and a half times the odds of having at least one NADC compared to 
those with no social problem (OR=2.47 [1.01-6.04]). Length on treatment was divided into two 
categories, below three years and above three years. Those respondents who had been on 
treatment for three years or above had almost six times the odds of having at least one NADC 
compared to  those who had taken treatment for less than three years (OR=5.87[1.36-25.4]). 
 
The respondents categories notably being actively followed up at the clinic (p<0.01), being lost 
to follow-up (p<0.01) and death (p=0.033) were associated with the presence of NADCs. 
Respondents who were actively followed at the clinic at the time were 40% less likely to have 
NADC compared to those who were not (OR=0.39 [0.22-0.72]).Outcome of death and being lost 
to follow up was associated with higher odds of having a NADC.  Respondents who died had 
three times the odds of having had an NADC compared to those who were alive (OR=2.90 [0.97-
8.61]). In comparison respondents who were lost to follow-up had nearly nine times the odds of 
having an NADC compared to those who were not lost to follow-up (OR=8.78[1.72-44.8]). 
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The following variables were not significantly associated with presence of NADCs: gender, non-
adherence to medications, and outcome of transfer to other facilities and second line or salvage 
regimen of HIV treatment. There was no differences in the prevalence of NADCs between males 
and females (p= 0.4). Adherence to medications did not show any association with presence of 
NADC (p=0.39). Respondents who were controlled on first line treatment showed no statistically 
significant difference in prevalence of one NADC when compared with those on second line or 
salvage treatment (p=0.7). Similarly respondents who had treatment switches did not show any 
statistically significant difference in prevalence of NADCs compared to those who were 
controlled on one treatment (p=0.23). Respondents who were transferred out to other facilities 
did not show any statistically significant differences in the prevalence of NADCs compared to 
respondents who had not been transferred to other facilities (p=0.3).  
 
The variables that showed associations with presence of NADCs namely: age, length of 
treatment, history of social problems and outcomes of death, loss to follow-up and being active 
on site, could not be fitted in a logistic regression model due to low numbers. These variables 
were analysed for potential associations with each other, to find out if they could be potential 
confounders. The age category of 50 years and above was associated with higher outcome of 
death (p=0.01), when compared to the age of below 50 years. Respondents who were aged 
50years and above had four times the odds of death (OR=3.95 [1.27-12.23]) compared to 
respondents who were aged less than 50 years. Potentially age could have confounded the 
relationship between presence of NADC and death. Respondents who had social problems in the 
past were statistically more likely to be lost to follow-up (p=0.007), compared to those who had 
no social problems. This meant that respondents who had social problems had six times the odds 
of being lost to follow-up (OR= 6.34 [1.41-28.6]) compared to those with no history of social 
problems. 
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Table 4.4 Prevalence of NADCs by socio-demographic and clinical variables 
Characteristic Presence of 
NADC 
(%)  
Absence of 
NADC 
(%) 
Crude Odds ratio 
(95% CI) 
 p value 
Gender  
          Male 
          Female 
 
25 (41.0)  
36 (59.0) 
 
65 (39.2) 
101( 60.8) 
 
1.08 (0.59-1.96) 
1 
 
             0.4 
 
Age (in years)    
          ≥50 
        < 50 
 
30(48.4) 
32 (51.6)  
 
44(26.5)  
 122 (73.5) 
 
2.96 (1.61-5.42) 
1 
          <0.001 
Presence of social 
problems 
     Yes 
     No  
 
10 (16.1)  
52 (83.9) 
 
12 (7.2) 
154 (92.8) 
 
2.47 (1.01-6.04) 
1 
 
           0.028 
Length of 
treatment (years) 
 
    ≤3 
    >3 
 
2 (3.2) 
60 (96.8) 
 
27 (16.4) 
138 (83.6) 
 
5.87 (1.36-25.4) 
1 
 
           0.007 
History of non-
adherence 
    Yes  
     No 
 
21 (33.8) 
41 (66.2) 
 
46 (27.7) 
118 (71.3) 
 
0.76(0.41-1.42) 
1 
 
             0.39 
Treatment line 
    Second/salvage 
   First line 
 
10 (16.2) 
52 (83.8) 
 
23 (13.9) 
143 (86.1) 
 
1.20 (0.53-2.68) 
1 
 
            0.7 
Treatment switches 
    Yes 
    No 
 
 
32 (51.6) 
30 (48.4) 
 
 
71 (42.8) 
95 (57.2) 
 
 
1.42 (0.79-2.56) 
1 
 
             0.23 
 
Active at site 
   Yes 
    No 
 
31 (50)  
31(50) 
 
119 (71.7) 
47(28.3)  
 
0.40 (0.22-0.72) 
1 
 
             0.002 
Death 
     Died 
     Alive 
 
7 (11.2)  
55 (88.70 
 
7 (4.22) 
159(95.7)  
 
2.90 (0.97-8.61) 
1. 
 
             0.033 
Transferred  out 
    Yes 
    No 
 
18 (29.0)  
44(71.0) 
 
38 (22.9) 
128 (77.1)  
 
1.38(0.71-2.66) 
1 
 
             0.3 
Lost to follow-up 
   Yes 
   No 
 
6 (9.7)  
56(90.3) 
 
2 (1.2) 
164 (98.8)  
 
8.78(1.72-44.8) 
1 
 
            0.006 
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As a primary outcome of interest virologic failure was assessed against exposure of the presence 
of NADC and it was not associated with the presence of NADC (p=0.3). In addition virologic 
status was assessed against several clinical and socio-demographic characteristics. There was a 
statistically significant association between non-adherence to medications and virologic 
treatment failure (p <0.001). Respondents who were not adherent to their HIV treatment had 
nearly thirteen times the odds of having virologic failure compared to those who were adherent 
(OR= 13.1[3.58-47.8]). Similarly respondents who were on second line or salvage HIV treatment 
were more likely to be in virologic treatment failure than those who were on first line HIV 
treatment (p<0.001). They had thirteen times the odds of having virologic treatment failure (OR= 
13.3[4.43-40.1]) compared to those on first line HIV treatment. Respondents who had switched 
treatment in the past, were more likely to have virologic treatment failure than those who had 
never switched treatment (p=0.02). Those respondents who switched treatment in the past had 
four times the odds of having HIV virologic failure (OR = 4.14 [1.29-13.26]). It was also 
observed on analysis that respondents who had social problems in the past were more likely to 
have virologic treatment failure (p=0.001). The respondents who had social problems in the past 
had six times the odds of having virologic treatment failure (OR = 6.26 [1.91-20.6]).  
 
Further statistically significant associations were revealed. Outcome of death was associated with 
virologic treatment failure (p=0.003). Respondents who died had five times the odds of having 
virologic treatment failure (OR= 5.08 [1.22-21.0]) compared to those who had not died. In 
converse it was observed patients who were followed up at the clinic site  were 20% less likely to 
have virologic treatment failure than those who were not actively followed at site by end of 2013 
(OR = 0.2 [0.06-0.61], p=0.003) 
 
The statistically significant associations of virologic treatment failure namely: treatment line, 
history of non-adherence, history of treatment switches, history of social problems, being active 
on treatment at site and death were subjected to logistic regression analysis, with the variable of 
presence of  NADC added a priori as the main exposure of interest in the study objective. Table 
4.5 shows the adjusted odds ratios. Finally the independent associations of virologic treatment 
failure were: being on second line or salvage treatment (Adjusted Odds Ratio (AOR) = 
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6.38[1.45-0.28.1], p = 0.014) and history of non-adherence to medications (AOR = 6.51 [1.62-
26.10], p = 0.008). 
 
The following associations were not significantly associated with virologic treatment failure: 
gender, age, presence of one NADC, presence of two NADCs, length of HIV treatment, being 
transferred to other clinics and being lost to follow-up. There was no differences in the 
prevalence virologic treatment failure for both males and females (p= 0.5). Similarly respondents 
who were aged 50 years and above did not show any statistically significant differences in 
prevalence of virologic failure compared those who were aged less than 50 years (p=0.6).In the 
same token respondents who had been on treatment for over three years had no statistically 
different prevalence of virologic treatment failure compared to those who were treated for three 
years or less. There was no statistically significant differences in prevalence of virologic 
treatment failure for respondents who had at least one NADC compared to those with no NADCs 
(p= 0.26).Similarly respondents with two NADCs did not show any differences in prevalence of 
virologic treatment failure when compared with those who did not have two NADCs (p=0.8). 
When compared with those on who were not transferred to other clinics, respondents who were 
transferred to other ARV clinics did not show any statistically significant difference in the 
prevalence of virologic treatment failure (p = 0.07). Likewise respondents who were lost to 
follow-up showed no statistically significant differences in their prevalence of virologic 
treatment failure compared to those who were not lost to follow-up (p=0.4)   
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Table 4.5 Virologic status by socio-demographic and clinical variables 
Characteristic 
 
Virologic 
Failure 
 
Virologic 
Control 
Crude Odds 
Ratio (95% CI) 
 
Adjusted Odds 
Ratio (95% CI) 
Gender  
   Male 
   Female 
 
6 (37.2)  
10 (62.5) 
 
82 (39.1) 
124 (60.9) 
 
0.91 (0.32-2.59) 
1 
 
Age category  
< 50 
   ≥50 
 
12 (75.0)  
4 (25.0) 
 
71 (34.3) 
136 (65.7)  
 
0.63 (0.19-2.05) 
1 
 
 
Treatment line 
  Second/salvage   
  First line 
 
10 (62.5)  
6 (37.5)  
 
23 (11.1) 
184 (88.9)  
 
13.3 (4.43-40.1) 
1 
 
6.38 (1.45-28.1) 
Presence of one NADC 
   Yes 
    No 
 
6 (37.2)  
10 (62.5) 
 
56 (27.1) 
151 (72.9)  
 
1.62 (0.56-4.66) 
1 
 
1.19 (0.33-4.30) 
Presence of  two NADC 
  Yes 
   No 
 
1 (6.25) 
15 (97.3) 
 
15 (7.2) 
192 (92.8) 
 
0.85 (0.11-6.91) 
1 
 
History of social 
problems 
     Yes 
     No  
 
5 (31.2)  
11 (68.8) 
 
14 (6.7) 
193 (93.3)  
 
6.26 (1.91-20.6) 
1 
2.69 (0.70-10.28) 
Length of treatment 
≤ 3 
>3 
2 (12.5) 
14 (87.5) 
26 (12.6) 
180 (87.4) 
1.01 (0.22-4.70) 
1 
 
Treatment switches 
Yes 
    No 
 
4 (25.0) 
12 (75.0) 
 
87 (42.0) 
95 (58.0) 
 
4.14 (1.29-13.26) 
1 
 
0.96 (0.19-4.68) 
History of non-
adherence 
   Yes 
   No 
 
 
3 (18.7)  
13 (81.3) 
 
 
51 (24.6) 
156 (75.4)  
 
 
13.1 (3.58-47.8) 
1 
 
 
6.51(1.62-26.10) 
Active at site 
   Yes 
    No 
 
5 (31.2)  
11 (68.8) 
 
143 (69.1) 
64 (30.9)  
 
0.2 (0.06-0.61) 
1 
 
3.37 (0.59-19.40) 
Death 
     Died 
     Alive 
 
3 (18.7)  
13 (81.3) 
 
9 (4.4) 
198 (95.6)  
 
5.08 (1.22-21.0) 
1 
 
2.71 (0.78-9.42) 
Transferred from site 
   Transferred 
   Not transferred 
 
7 (43.7)  
9 (56.3) 
 
48 (23.2) 
159 (76.8)  
 
2.58 (0.91-7.2) 
1 
 
Lost to follow-up 
    Yes 
     No 
 
1 (6.2) 
15 (93.8) 
 
7 (3.4) 
200 (96.6) 
 
1.9 (0.22-16.5) 
1 
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CHAPTER 5. DISCUSSION OF RESULTS 
 
5.1 Study design, limitations and impact on results 
The study limitations are that this study had financial and time constraints.  There was limited 
sponsorship for material resources and data clerks for only two weeks. As a result the study 
could not be done for a longer time period, in which all sampled files could be traced.  Therefore 
there could be some misclassification bias, with the non-responders. If there was no time 
constraint, the sampled files could have been obtained making sure that the level of bias was 
reduced. It is always common that files that were not available at their position were associated 
with some problems such as relating to treatment, or would have necessitated discussions with 
other doctors. So there is a possibility that such non response cases could have contributed 
significantly to the outcomes. It then remained that for the rest of the study the principal 
investigator was also involved with the records including ensuring that they were all filed 
appropriately. Nevertheless there were no major patient outcomes relating to filing of the records 
as there was reliable assistant from the clinic staff. To cater for measurement bias, associated 
with this positivist study, at the last two days of transcription, a medical doctor who did not take 
part in the pilot, assisted in the transcription of the records. This intervention was made to ensure 
that the researcher expectations of outcome were not predominantly skewing data. A more 
appropriate solution would have been to use independent data capturers who were conversant 
with the study to capture the data, without using the investigator. This option was not available 
due to funding constraint.  
 
Whilst this cross sectional study showed there is a problem of NADCs, the magnitude of the 
problem might be more or less pronounced. To begin with the sample size calculation used a 
general population statistic of 2010 as an estimate of prevalence. There is a possibility that the 
sample size may have been inadequate. Utilising the study result prevalence, the desirable 
sample size is slightly more (330). There are some pertinent findings that were observed with 
regard to the operations of the clinic. It was worrying that documentation of some key socio-
economic data such as marital status, smoking status, alcohol use and employment status were 
not routinely captured. These may not have been found important for an outpatient clinic, 
however it may arguably be emphasized that such details are also important in clinical decisions. 
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It was explained that such data were captured as a once off record but it was observed that the 
information was not seen in all the files. The absence of these important socio-demographic 
details meant that they could not be assessed in the analysis. It is of concern as some of these 
factors such as smoking and alcohol use are involved in the aetiology of NCDs. They could have 
acted as confounders that could have been analysed, had they been available. 
 
It was also clear that the computer based in patient management system is used mainly for 
booking patients and for ordering investigations. However, by and large a standardized form of 
keeping the OPD notes was in use and it was adequately completed.  This was evidenced by 
having only one record excluded based on legibility.  There was a concern that there were some 
missing data that should have been kept such as viral load, and location of living in the OPD 
notes.  Nevertheless, as a source record, the OPD records were able to provide required 
information. 
 
There was however one observation made relative to documentation. It appeared that problems 
of the NADCs and HIV were not routinely documented. From all the 80 cases with non-AIDS 
defining problems, there was scanty documentation of problems caused by NADCs relative to 
HIV treatment. Furthermore, there was an observation that reasons of switches were also not 
readily documented.  
 
In using the multiple logistic regression analysis, the assessment was also limited to few 
potential confounders notably age, NADC presence social problems, non-adherence to 
medications and an outcome. This was because the sample size was not large enough to include 
more potential confounders in the test. Stratified analysis was also not possible for some of the 
associations with NADCs due to the small numbers. 
 
The study design and lack of a uniform sampling frame had an influence and possibly bias on the 
study. Selection bias was noted in having a total non-response rate of 24%. This was 26% in the 
active patients, 6.6% in dead patients records, 8.3% in the transferred out patients records and 46 
percent in lost to follow up group. As had been noted the prevalence in all these groups is 
different. Had more of the active files been available, the possibility is that the outcome could 
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have been different. Nevertheless, it was decided that these files would not be actively searched 
for as it had been learnt that some files are almost always lagging behind in filing. Such files are 
kept at various staff offices and searching for them would have been a laborious exercise. 
 
The study was limited to outpatient’s hard copies and electronic records were used to only 
corroborate the non-naming file identifier. This was essentially due to time constraints. It also 
became apparent that the electronic records had not been actively updated consistently for the 
last two years due to shortage of staff. They could have been used to document blood 
investigations and results, however according to Ministry of Health policy; data collected over 
6months or more is archived and protected. Access to these would have required clearances, a 
task, which was not feasible at that point in time.  
 
As commonly expected in a cross sectional study, the associations that were confirmed, and their 
lack thereof,  have less bearing on causality because of the nature of evidence related to this type 
of study. Therefore, the relationship between age and NADCs, outcome of death and loss to 
follow-up to presence of NADC would bear more weight if it were a different study design such 
as prospective case cohort. 
 
5.2 Characteristics of respondents 
The age range and the sex ratio are concomitant with an adult ARV treatment site, with the 
clustering of patients at the age category of 31-60 years being reported in some sites in Botswana 
in the past (Bene and Darkoh, 2014). A more recent cross sectional study revealed age 
distribution that has the same pattern as the one observed in the current study (Ehlers and 
Tshisuyi, 2015). Most of these studies show predominant attendance of clinics by females, an 
observation that was observed in the current study. The other end of the age bracket indicates 
that a geriatric population needs to be catered for in HIV care. Indeed there were 4 patients aged 
over 65 years and over 34 who were aged 55 years and above. These age categories were also 
represented by Bene and Darkoh (2014) and similarly Ehlers and Tshisuyi (2015).  This study 
age and gender demographics was therefore consistent with other similar studies in an HIV-
infected population, on ART in Botswana. 
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The distribution of patient location in those who showed a record of location is also in agreement 
with the IDCC criteria. It is observed that over 64% were patients within the clinic’s catchment 
area. However it is noted that some were from locations, which were over 500km away from the 
clinic. This is understandably a group for whom care has to be optimized, following their 
referral, either due to treatment problems, co-morbidities or any complications that needed 
specialist care. An analysis of the categories of location of living against prevalence of NADC or 
virologic status was not considered owing to the 24 returned missing entries for location of 
living. Therefore whilst the analysis showed no statistically significant association with the two 
attributes, that may not have been the case if the 24 missing entries were recorded. 
 
Previous problems of compliance were documented in the form of documented reported missed 
doses, defaulting of treatment including recurrent defaults. This included mild forms where few 
doses were missed, deliberate missing of several doses and stopping of treatment. Observation of 
compliance problems in 29.4% of this cohort is an outcome worth noting. Weiser et al. (2013) 
studied compliance problems, in three clinics in Botswana and reported compliance rate of 56% 
by health worker assessment in the cohort. This meant lack of compliance of 44%. They also 
observed an agreement between health provider and patient reported compliance of 68%. The 
current study statistic, although is better than Weiser et al. (2013), still raises concern. The two 
studies are similar in that they are both cross sectional studies, however they differ in that in the 
medical records both health provider and patient reported compliance were at interplay, as was 
with this study.  
 
The former study used patient interviews. It is also worth noting that Weiser et al. (2003) and 
this study definitely do not compare like with like as their definitions of compliance by the 
former study were more thorough than in this study. A blunt comparison of both studies however 
is that the reported health worker assessment of compliance, showed improvement comparing 
the situation in 2000, as investigated by  Weiser et al. (2003), and findings of the present study 
for 2013.  
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The adherence rate observed in the current study of 70.1% can be compared to Kgatlwane et al. 
(2006) at 77% and Weiser et al. (2003) of 54%. These cannot be arguably assumed to show an 
improvement in adherence over the years from 2003. The difference in study measurement 
methods is appreciated. Kgatlwane et al. (2006) used three measures that were averaged: pill 
count, two day adherence recall and user reported adherence. The authors averaged the three 
types of adherence   statistics to arrive at the statistic of 77%. The current study utilized health 
care provider reported adherence from the chart. Garber et al. (2004) reviewed the literature on 
concordance of self reported adherence and other measures and found varying concordance of 
the various measures.  
 
It may therefore not be justified to compare the three studies above. It is noted that the study 
designs for the three studies are different and, therefore, not completely comparable. However, a 
period prevalence of non-adherence of 29.4% in this cohort shows that adherence to HIV 
medication was still a problem that should be addressed in this setting. Moreover, some of the 
cases were defaulters who had been reinitiated on treatment more than twice in their care. This 
area of HIV care is certainly an area of much needed research and policy intervention, as it has 
tremendous morbidity and cost implications. 
 
5.3The prevalence of non-AIDS defining conditions 
The prevalence of these conditions of 350 patients per 1000 in 2013 is significant and is a 
yardstick for which future reference could be measured. The prevalence of hypertension in this 
group was 17.5%. In addition, hypertension with either hyperlipidaemia and diabetes or 
lipodystrophy showed a prevalence of 2.6%, and that being 15% of all hypertensive patients. 
Other than the fourth criteria of insulin resistance (Sekhar et al., 2004), which was not routinely 
investigated, this group of patients had at least two or three conditions that commonly defined 
the metabolic syndrome by most criteria.  
 
Various studies have shown equivocal findings of the prevalence of hypertension on HIV 
positive patients compared to HIV negative controls. Whilst Bergersen et al. (2003) and Jerico et 
al. (2005) showed a similar prevalence of hypertension on the HIV positive patients and controls, 
Gazzaruso et al. (2003) have shown significant differences. The prevalence of hypertension in 
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Botswana in general population was estimated at 33.1% in 2007 according to the STEPS survey 
and a further study on its prevalence was done in 2014 (African Union, 2013). This study will go 
a long way in demonstrating the comparability of these rates when the 2014 STEPS results are 
out.  It may not be advisable to be quick to point out the results of this NADC study as an 
indication of a lower hypertension prevalence compared to the general population since STEPS 
statistic was for 2007. This clearly calls for further studies with more resources to elucidate the 
magnitude of the problem.  
 
Dusara et al. (2009) documented a prevalence of hypertension of 18.5% on an HIV positive 
cohort in Botswana in 2009. The prevalence in the current study is comparable to Dusara et al. 
(2009). It must however be noted that that cohort was a HAART naive group as compared to this 
study where all patients had been on treatment. This was an important finding since Dusara et al. 
(2009) study was from the TSHEPO study which was one the first randomised trials that 
established safety of antiretroviral treatment in Botswana. The fact that this study corresponds to 
a higher level study in the form of a clinical trial is an important finding. Furthermore, the cohort 
of Dusara et al. (2009) was later transferred to the current study site. The prevalence of 
hypertension compares to 26.2% reported by Kagaruki et al. (2014) observed in a cross sectional 
study in an urban setting in Tanzania. 
 
It is noted that the three (3) cases of cancer were registered all at an advanced stage. It has been 
shown that a significant proportion of non-AIDS associated cancers seem to be more prevalent in 
HIV positive cases (Ruiz, 2009). It had further been suggested that cancers in HIV-infected 
patients tend to be more aggressive than in the non HIV-infected (Silverberg and Abrams, 2007; 
Patel et al., 2008). This may account for why all the cancers noted in this cohort were at an 
advanced stage. Pertaining to prevalence of cancer in the cohort, there were no available data to 
compare prevalence statistics for cancer in Botswana. 
 
It is important to note that this group of patients is expected to have a high hypertension and 
indeed non-AIDS defining conditions. As detailed before, the criteria for admission into Princess 
Marina Infectious Diseases Care Clinic, is that the patients should have problems with their 
treatment, have co-morbidities or be resident in the clinic catchment area. Therefore a high 
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prevalence rate of chronic diseases and hypertension is expected. It is assumed that such a 
situation would not have to be the case in all other clinics. This was also corroborated by the 
lower prevalence in the transferred out patients than in the active patients. Transferred out 
patients form part of the peripheral clinics clientele and such patients HIV treatment would have 
been stabilised. It would therefore be expected that those with co-morbidities would stay with 
Princess Marina Infectious Diseases Care Clinic. 
Bergersen et al. (2003) and Baekken et al. (2008) noticed an equal prevalence of hypertension in 
the group with HIV and general population and those who are HAART naive. However Baekken 
et al. (2008) reported significant proportion of hypertension in patients who had treatment of 
HAART for over 5 years. In this particular study the length of treatment on HAART was not 
associated with hypertension. Such a difference in Baekken et al. (2008) compared to the current 
study could be affected by study design as the former used a case control study as opposed to a 
cross sectional archive study. It would perhaps be better left for further research. Several authors 
have argued that the hypertension is often increased in HAART patients by a metabolic 
syndrome that is more associated with HAART (Blanco et al., 2010; Jerico et al., 2002). There is 
also another version that attributes this to the length of period of a chronic HIV infection 
affecting cytokine cascades. 
 
It is noted that osteoporosis and osteopenia was not noticed anywhere in the records. This was 
contrary to Hirschhorn et al. (2012) estimate that these two conditions have ten-fold prevalence 
in HIV patients on HAART. A possibility could be that the condition was not investigated or 
suspected. A criterion for confirmation of osteoporosis and osteopenia requires bone density 
scans and other blood investigations such as calcium and hormonal profile may be needed 
(Kanis, 2015). There was an observation that bone density scans were not routinely taken in this 
setting. There is a significant observation that some patients were taking medication that can 
potentially cause osteopenia. It is noted that tenofovir has been significantly associated with 
osteopenia and osteoporosis (Hirshhorn et al., 2012; Knobel et al., 2001). It is suspected that 
these conditions are less reported. In addition in the column of data capture remarks, more than 5 
patients had indicated that they experienced chronic pain of some sought. Two cases of 
osteoarthritis were recorded. 
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Alcohol abuse occurred as the main psychiatric/psychological disorder that occurred in this 
setting alongside a case of schizophrenia. Perhaps unexpectedly mood disorders were not 
observed in this cohort. It must however be noted that several records showed concerns of 
psychological stress issues and were referred to social work department. Such could have 
appeared as mood disorders in definitive diagnoses in the other outpatient departments. 
 
5.4 Associations of non-AIDS defining conditions 
The association of age with presence of NADC is expected, because it is a known fact that 
chronic disease prevalence increases with age. In addition some studies have shown correlations 
of multi morbidity with age; even in the HIV population (Rodriguez-Penney et al., 2013).There 
was no association of presence of NADCs with gender. Some studies have shown certain 
conditions prevalence predisposition to male e.g. hypertension as was seen in some studies on 
HIV positive patients (Baekkam et al., 2003). This was not seen in this particular cohort. 
 
Prevalence of NADCs was higher in patients who had been on ART longer than three years in 
comparison with those who had been on treatment for less than three years. This is to be 
expected since treatment of HIV is associated with conditions such as lipodystrophy that arise as 
a result of the side effects of medications. 
 
In the cohort for the present study, clinic outcomes of death and loss to follow up were 
associated with the presence of NADCs. This is an observation worth visiting. It suffices to say 
the presence of a diseased state is perhaps always associated with higher possibility of death than 
none diseased state. Said in another way, it can be held that NADCs significantly caused death in 
this cohort. In this study design it is always an inherent weakness of causality in any association 
that is observed. Another study type e.g. case control type assessing a group of mortalities of 
NADCs on HAART compared to NADCs without HAART would probably have more strength 
in causality. Such mortality studies have shown significant contribution of NADCs to HIV-
infected population (Hooshyar et al., 2007).  
 
Brinkhof Pujades-Rodriguez and Egger (2009) summarized studies on patient who were lost to 
follow-up, whilst on ART programmes in resources limited settings in a meta-analysis. The 
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review showed that in the studies 20 to 60% of patients who were lost to follow-up died. In 
addition 34% of the patients who were traced and found to have died had the cause of death as 
non-AIDS defining illnesses. Therefore the current study corroborates with Brinkhof et al. 
(2009) in the contribution of NADCs in patients who were lost to follow-up. The common 
reasons for not returning to the clinic in Brinkhof et al. (2009) review were transfer to another 
programme, financial problems and improving or deteriorating health. These reasons might have 
been at play in the current study and it is important to notice that loss of follow-up due to 
improving or deterioration might reflect a lack of understanding or the need for life-time 
treatment regardless of state of health,  
 
The physical burden of multi-morbidity has been associated with psychosocial distress and 
psychological illness (Mendenhall et al., 2012). Their study showed that having these conditions 
was a burden on the patients and that caused them distress. It could be that such factors 
contributed to losses to follow-up where in the clientele multi-morbidity caused the patients to 
default follow-up. This remains an area for research, and may give insight into the problem of 
multi-morbidity. Indeed it has been shown in a systematic analysis that caring for co-morbidities 
demands targeted interventions for the population, especially risk factors and functional 
disabilities (Smith et al., 2012). 
 
In this cohort the first line failure rate was 3.16%. It was observed that 30.10% of those in 
second line or salvage were in failure. As a result there was an association of being in failure 
related to second line or third line. These results have to be looked at in the context of the study 
site. As a snap shot 30.10% of those on second line or salvage were failing. However the 
Princess Marina ART clinic follows up stable patients routinely, twice a year, and failing patients 
more frequently. It may mean that in the subsequent visits that were not recorded in the year such 
second line patients would not be failing. This could explain the high second line failure rate. 
 
5.5 Treatment of HIV and Non-AIDS Defining Conditions 
In this study, in relation to treatment of NADCs it was observed that 21.2% of the conditions 
control was not documented either due to the fact that the treatment was given in another clinic 
or that documentation was not indicated.  
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This study could not adequately assess the treatment or compliance to the Botswana HIV 
Treatment Guidelines, however, on a general observation; the treatment was in accordance with 
the guidelines. Almost all recommended regimen were as stipulated. However a stepwise 
interrogation of the changes could not be assessed and was beyond the document scope. 
 
It is noted that the first line failure rate was 3.16% closely linked to the reported statistic of 3% 
given by Princess Marina Infectious Diseases Care Clinic annual statistics, 2013. Overall 7.2% 
were in virologic failure. It is also observed that 30.10% of those in second line or salvage were 
in failure. This is important and must be interpreted appropriately. Of relevance is that such 
patients are seen several times and may have at certain times in the same year converted back to 
virologically controlled status. Such is the inherent weakness of a cross sectional study on an 
outcome that can revert to normal. As a prevalence statistic 30.10% of those in second line or 
salvage therapy, were in virologic failure.  
 
The treatment of the two common conditions hypertension and hyperlipidaemia were looked at 
and in particular the control of the conditions was assessed. An observation that was common to 
all the NADCs is that a significant proportion of hypertension and hyperlipidaemia were 
uncontrolled. Nevertheless the treatment categories observed are suggestive of adherence to the 
Botswana National Treatment Guidelines, 2007 with lifestyle modifications and single drug 
diuretic and calcium channel blocker being the majority. As with HIV treatment a stepwise 
interrogation could not be done. 
 
 
 
 
 
  
 
 
 
 
 52 
 
CHAPTER 6. CONCLUSIONS AND RECOMMENDATIONS 
 
6.1 Conclusions 
A prevalence of a group of non-AIDS defining illnesses and conditions was determined at 35% 
translating to 350 per 1000 of population of attendees of the Princess Marina Hospital adult 
antiretroviral clinic for the year 2013. This prevalence varied along represented outcome groups 
of the cohort at the end of 2013. For patients who remained active at the site in December 2014, 
the prevalence ratio comparing those who were active at the clinic to the whole group was 0.70. 
For those who were transferred out the prevalence ratio was 1.24. These were in comparison 
with prevalence ratios of NADCs of 2.04 and 2.86 for those who died and those who were lost to 
follow-up respectively, still using the whole sample population as reference. There were 
associations of having NADCs to age, outcome of death and lost to follow-up and having social 
problems. There was no association of NADCs to virologic treatment failure. This study 
confirms significant morbidity related to non-communicable diseases in HIV population on 
treatment. As a one-time traverse of the problem, this study alone cannot, and is not expected to 
instruct policy change. However, it calls for further research on possible policy changes. An 
integrated management of chronic diseases may be advocated for. This is in relation to the large 
proportion of patients who had their other conditions managed elsewhere.  
 
The study, like many other studies previously, shows non-adherence to HIV treatment as one of 
the major determinants of virologic failure. 
 
6.2 Recommendations 
The prevalence of these chronic diseases and the associations elicited call for further research 
into these conditions.  It also appeals for strategies to manage these conditions alongside HIV as 
a concerted effort and not fragmented. Perhaps what has been emulated for TB and HIV may be 
warranted in NADCs management. For example, managing cardiovascular diseases in a 
combined Cardiovascular and HIV clinic may help address the combined morbidities. Such 
policy decisions may not come without further research. The magnitude of this problem may not 
have been represented accurately due to the study limitations and may call for more studies in 
relation to these conditions.  
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The following recommendations are made: 
 Documentation at the ARV clinics should include social determinants such as marital status, 
smoking and alcohol use.  
 More studies should be done for other ARV clinics to appreciate this problem. It is advocated 
that one or more studies with more weight such as prospective cohort be done to elucidate the 
problem of chronic non communicable diseases in HIV. 
 Other type of studies such as case control study may be necessary to find out causality 
particularly in relation to outcomes such as death and loss to follow-up. It is felt that other 
conditions may have been recorded elsewhere in the year 2015 e.g. Emergency Room and 
Vascular clinic. 
 There is a need to explore using integrated clinics for patients with both NCDs and HIV to 
find if there might be a benefit for these patients with multi-morbidity. 
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APPENDIX 1 Data capture tool 
Research 
number 
(research 
identifier) 
Age Gender(M=mal
e F=female) 
Location of 
living in KM 
1=within 20km, 
2= within 
40Km, 
3=within 
100km, 
4=within 
500km 5= over 
500km 
Has there ever 
been a 
compliance/adher
ence problem in 
the past? 
(YES/NO) 
Were there any 
of the following 
social issues 
(specify 
relevant): 
1.Transport 
2.Family 
problems 3. 
Personal 
problems 
4.Other social 
problems 
HIV 
treatment 
line 
(specify) 
Treatment 
line  1= first 
line 2 
=second 
line 3= 3rd 
line salvage 
 (non name 
identifier) 
         
 Year of first 
treatment 
Previous 
treatment 
switches 
(YES/NO) 
SWITCHES Initial CD4 count 
(cells/mm3) 
Last CD4 count 
in 2013 
(cells/mm3) 
Last 
virological 
level in 
2013 
 
Outcome of 
patient 
(1=Active 
2= 
Transferred 
out 3=Loss 
Virologic 
status 
(1=Controlle
d 2=Failure) 
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to follow-
up 4. Died) 
         
Is there a 
non-AIDS 
defining 
condition 
shown in 
the record? 
-NADC1 
(YES/NO) 
Specify 
NADC 1 
Specify-List the treatment of 
NADC1  
List the problems 
relating to 
NADC1 and 
ARV 
Were there any problems warranting change 
of treatment of HAART or NADC relating 
to either HAART or NADC treatment? 
What is the 
level of 
control of 
the NADC 
?(controlled, 
uncontrolled, 
progressive, 
unknown) 
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Is there a 
non-AIDS 
defining 
condition 
shown in 
the record 
NADC2? 
(YES/NO) 
Specify 
NADC2 
Specify-List the treatment of 
NADC 2 
List the problems 
relating to 
NADC2 and 
ARV 
Were there any problems warranting change 
of treatment of HAART or NADC2 relating 
to either HAART or NADC treatment? 
What is the 
level of 
control of 
the NADC 
?(controlled, 
uncontrolled, 
progressive, 
unknown) 
      
Is there a 
third non-
AIDS 
defining 
condition 
shown in 
the record 
NADC3 
(YES/NO) 
Specify 
NADC 3 
Specify-List the treatment of 
NADC3 
List the problems 
relating to 
NADC1 and 
ARV. 
Were there any problems warranting change 
of treatment of HAART or NADC relating 
to either HAART or NADC treatment? 
What is the 
level of 
control of 
the NADC? 
(controlled, 
uncontrolled, 
progressive, 
unknown) 
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Is there 
evidence of 
more than 
three 
NADCs 
Specify List 
the NADCs  
Specify list treatment of the 
NADCs Treatment 
Specify-list 
problems of 
NADC and ARV 
Was there any problems warranting change 
of treatment of HAART or NADC 
What is the 
level of 
control of 
the NADCS 
?(controlled, 
uncontrolled, 
progressive, 
unknown) 
Data capturer's remarks 
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